Phase 4Status unknown
Comparison of semeglutide and semeglutide plus sodium-glucose cotransporter-2 inhibitors on participants with type 2 diabetes and MAFLD
- Sponsor
- Xiamen Humanity Hospital
- Enrollment
- 35 planned
- Conditions
- type 2 diabetes participants with metabolic dysfunction-associated fatty liver disease
- Interventions
- Semaglutide + sodium-glucose cotransporter-2 inhibitors; Semaglutide + placebo
- Ages
- adults, older adults
- Registry
- ChiCTR2600134083
Full record on the Chinese Clinical Trial RegistrySource: WHO ICTRP, processed October 12, 2026
Primary outcomes
- Degree of fatty liver
- Free Fatty Acids in Blood
- Diabetes Remission Rate;
History
Last registry update
Registered
Started